New action plan to foster development of advanced therapies
Actions address specific challenges identified by stakeholders
The European Commission's Directorate-General for Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA) recently published a joint action plan to foster the development of advanced therapy medicinal products (ATMPs). The main aim is to streamline procedures and better address the specific requirements of ATMP developers.
ATMPs are medicines for human use that are based on genes or cells. These therapies offer ground-breaking new opportunities for the treatment of disease and injury. They are particularly important for severe, untreatable or chronic diseases for which conventional approaches have proven to be inadequate.
ATMPs can be classified into four main groups: gene therapy medicinal products, somatic cell therapy medicinal products, tissue engineered medicinal products and combined ATMPs. EMA has received 18 marketing authorisation applications since the ATMP regulation came into force in 2009. Nine products have been approved.
The Agency's Committee for Advanced Therapies (CAT) plays a central role in the scientific assessment of ATMPs, as it provides the expertise needed to evaluate these medicines. Other initiatives include European Commission research programmes, the innovation offices in the national competent authorities and EMA’s PRIME scheme.
At international level, a regular forum for dialogue has been set up with the United States Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to share experience on ATMPs. EMA and the CAT also contribute to the cell therapy group and gene therapy groupof the International Pharmaceutical Regulators’ Forum (IPRF).
DG SANTE and EMA, in collaboration with the Member States' competent authorities, are working on some initiatives to support the development and authorisation of high quality, safe and effective ATMPs. The plan published today contains 19 actions in different key areas. Some of the actions are already in place, others are new. Actions were also informed by the ideas collected during a multi-stakeholder workshop hosted by EMA on 27 May 2016. The workshop aimed to explore solutions to identified challenges in the development of ATMPs. Topics discussed ranged from the need for early interaction and guidance from regulators, to more transparency and information sharing, greater harmonisation between Member States in various aspects of ATMP regulation and measures to tackle inequalities in patient access to ATMP treatments.
Examples of upcoming actions in the plan include:
- European Commission guideline on good manufacturing practice for ATMPs, to reduce the administrative burden and adapt the manufacturing requirements to the specific characteristics of ATMPs;
- initiation of dialogue with national competent authorities to address the interplay between the legislation on genetically modified organisms (GMO) and on medicines,to reduce discrepancies across the European Union (EU) regarding the application of GMO rules;
- new EMA scientific guidelines on ATMPs, including investigational ATMPs, to clarify regulatory expectations;
- continuous awareness and training sessions organised by EMA for the EU network on ATMP-related topics.
DG SANTE and EMA will continue monitoring the field and propose further initiatives as appropriate.
- Advanced therapies: research & development
- Advanced theraoies: overview
- Committee for Advanced Therapies (CAT)
- Multi-stakeholder advanced therapy medicinal products (ATMPs) expert meeting: exploring solutions to foster ATMPs’ development and patient access in Europe (27/5/2016)
Latest News from
Council and Parliament reach provisional political agreement on access to Union waters, extending the current rules for fishermen for another ten years30/09/2022 15:25:00
The Czech Presidency of the Council of the European Union and the European Parliament reached a provisional political agreement as regards the regime for access of fishing vessels to member states’ territorial waters.
Ensuring radiation protection: Commission refers LATVIA to Court to guarantee citizens' protection from ionising radiation-exposure risks30/09/2022 14:33:00
The Commission is taking legal steps to ensure the protection of citizens, workers and patients against the dangers arising from exposure to ionizing radiation.
Investor citizenship scheme: Commission refers MALTA to the Court of Justice30/09/2022 13:25:00
The European Commission yesterday decided to refer Malta to the Court of Justice of the European Union for its investor citizenship scheme, also referred to as the ‘golden passports'.
Human rights: EU increases support to the protection of human rights defenders worldwide30/09/2022 12:38:00
Human rights are increasingly under threat worldwide. Against this global backdrop, reconfirming the European Union's strong support to human rights, fundamental freedoms and democracy, and their defenders worldwide, Commissioner Jutta Urpilainen yesterday signed €30 million, a substantial increase, for the new phase of the EU Human Rights Defenders Mechanism, in the presence of civil society organisations and human rights defenders, for the period 2022–2027.
Circular economy: Commission takes action to reduce waste from single-use plastics30/09/2022 11:33:00
The Commission is taking legal steps against 11 Member States, calling on them to step up the implementation of the Single-Use Plastics Directive in order to reduce the impact of certain plastic products on the environment and on human health.
European Citizens' Initiative: Commission decides to register a new initiative on learning disabilities30/09/2022 10:38:00
The Commission recently (28 September 2022) decided to register a European Citizens' Initiative (ECI) entitled ‘Focus on Specific Learning Disabilities on EU Level'.
State aid: Commission approves €700 million Italian scheme to support companies in context of Russia's war against Ukraine30/09/2022 09:25:00
The European Commission has approved a €700 million Italian scheme to support companies in the context of Russia's war against Ukraine.
Speech by Commissioner Gentiloni at the Atlantic Council Frankfurt Forum29/09/2022 16:33:00
Speech given yesterday by Commissioner Gentiloni at the Atlantic Council Frankfurt Forum.
Press statement by President von der Leyen on a new package of restrictive measures against Russia29/09/2022 15:25:00
Press statement given yesterday by President von der Leyen on a new package of restrictive measures against Russia.
Global Gateway: European Commission and the European Bank for Reconstruction and Development deepen their partnership to boost private sector investment in partner countries29/09/2022 14:33:00
The Commissioner for International Partnerships, Jutta Urpilainen, and Odile Renaud-Basso, President of the European Bank for Reconstruction and Development (EBRD), yesterday signed a new Financial Framework Partnership Agreement (FFPA) between the European Commission and the EBRD to boost investment in sustainable infrastructure and private sector development and to cooperate for example on issues such as nuclear safety.